摘要
目的:探讨达格列净联合沙库巴曲缬沙坦钠对左心衰竭合并肺动脉高压患者心脏功能的改善效果。方法:选取2020年7月-2021年7月九江市第一人民医院收治的126例的左心衰竭合并肺动脉高压患者,按照随机数字表法将其分为对照组和观察组,每组63例。两组均实施基础治疗,对照组在此基础上实施沙库巴曲缬沙坦钠治疗,观察组在对照组基础上联合应用达格列净。比较两组心功能、肺功能及生活质量改善情况。结果:治疗前,两组左心室射血分数(LVEF)、6 min步行距离(6MWD)、左室收缩末内径(LVESD)、左室舒张末内径(LVEDD)、最大呼气流量(PEF)、一秒用力呼气容积(FEV_(1))、第一秒用力呼气量占所有呼气量的比值(FEV_(1)/FVC%)、各维度明尼苏达州心功能不全生命质量量表(MLHFQ)评分及总分比较,差异均无统计学意义(P>0.05)。治疗4周后,两组LVEF、6MWD、FEV_(1)、FEV_(1)/FVC%水平均高于治疗前,LVESD、LVEDD、躯体、情感、其他领域评分和MLHFQ量表总分均低于治疗前,且观察组LVEF、6MWD、FEV_(1)、FEV_(1)/FVC%水平均高于对照组,LVESD、LVEDD、躯体、情感、其他领域评分和MLHFQ量表总分均低于对照组,差异均有统计学意义(P<0.05)。结论:将达格列净联合沙库巴曲缬沙坦钠应用在左心衰竭合并肺动脉高压中,可促进心肺功能的改善,提升患者活动能力,改善生活质量。
Objective:To explore that application effect of Dapagliflozin combined with Sacubitril Valsartan Sodium on the improvement of cardiac function in patients with left heart failure complicated with pulmonary hypertension.Method:A total of 126 patients with left heart failure complicated with pulmonary hypertension admitted to Jiujiang NO.1 People’s Hospital from July 2020 to July 2021 were selected,they were divided into control group and observation group according to the numerical random table method,with 63 patients in each group.Both groups were treated with basic treatment,the control group was treated with Sacubitril Valsartan Sodium on this basis,and the observation group was combined with Dapagliflozin on the basis of the control group.The improvement of heart function,lung function and quality of life were compared between two groups.Result:Before treatment,there were no significant differences in left ventricular ejection fraction (LVEF),6 min walking distance (6MWD),left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD),maximum expiratory flow (PEF),forced expiratory volume in one second (FEV_(1)),ratio of forced expiratory volume in one second to all expiratory volume (FEV_(1)/FVC%),and Minnesota living heart failure questionnaire (MLHFQ) in all dimensions scores and total scores between two groups (P>0.05).4 weeks of treatment,the levels of LVEF,6MWD,FEV_(1) and FEV_(1)/FVC% in both groups were higher than those before treatment,and the LVESD,LVEDD,scores of physical,emotional,other fields and MLHFQ total scores were lower than those before treatment,and the levels of LVEF,6MWD,FEV_(1) and FEV_(1)/FVC% in the observation group were higher than those in the control group,the LVESD,LVEDD,scores of physical,emotional,other fields and MLHFQ total score in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).Conclusion:The application of Dapagliflozin combined with Sacubitril Valsartan Sodium in the
作者
汤曾耀
梅寒颖
TANG Zengyao;MEI Hanying(Jiujiang NO.1 People’s Hospital,Jiangxi Province,Jiujiang 332001,China;不详)
出处
《中国医学创新》
CAS
2022年第14期1-5,共5页
Medical Innovation of China
基金
江西省卫生健康委科技项目(SKJP220201409)。
关键词
左心衰竭
肺动脉高压
达格列净
沙库巴曲缬沙坦钠
Left heart failure
Pulmonary hypertension
Dapagliflozin
Sacubitril Valsartan Sodium
